Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice

Inflammopharmacology. 2019 Feb;27(1):167-173. doi: 10.1007/s10787-018-0536-3. Epub 2018 Oct 5.


Multiple sclerosis (MS) is an autoimmune disease leading to the destruction of myelin with consequent axonal degeneration and severe physical debilitation. The disease can be treated with immunosuppressive drugs that alleviate the symptoms and retard disease aggravation. One such drug in clinical use is glatiramer acetate (Copaxone). The non-psychotropic immunosuppressive cannabinoid compound cannabidiol (CBD) has recently been shown to have beneficial effects on experimental autoimmune encephalomyelitis (EAE). The aim of our study was to compare the efficacy of CBD and standardized extracts from a CBD-rich, ∆9-THClowCannabis indica subspecies (Avidekel) with that of Copaxone. Our data show that CBD and purified Avidekel extracts are as efficient as Copaxone to alleviate the symptoms of proteolipid protein (PLP)-induced EAE in SJL/J mice. No synergistic effect was observed by combining CBD or Avidekel extracts with Copaxone. Our data support the use of Avidekel extracts in the treatment of MS symptoms.

Keywords: Avidekel extracts; Cannabidiol (CBD); Cannabis; Experimental autoimmune encephalomyelitis (EAE); Immunosuppression.

MeSH terms

  • Animals
  • Cannabidiol / pharmacology*
  • Cannabis / chemistry*
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Female
  • Glatiramer Acetate / pharmacology*
  • Immunosuppressive Agents / pharmacology
  • Mice
  • Multiple Sclerosis / drug therapy*
  • Plant Extracts / pharmacology*


  • Immunosuppressive Agents
  • Plant Extracts
  • Cannabidiol
  • Glatiramer Acetate